D-0379-2026 Class II Ongoing

Recalled by Harbin Jixianglong Biotech Co., Ltd. — Haerbin, N/A

FDA drug recall D-0379-2026 was initiated by Harbin Jixianglong Biotech Co., Ltd. on Feb 13, 2026 and is designated Class II. Reason for recall: CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Mar 11, 2026
Initiation Date
Feb 13, 2026
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China

Reason for recall

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Distribution pattern

Nationwide within the United States

Code information

Lot #: CP-030-20250711, Exp. Date Jul. 24th, 2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0379-2026
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0379-2026. Report a data issue: hello@regdatalab.com.